Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy

[1]  A. Goldstein,et al.  Adaptation or selection—mechanisms of castration-resistant prostate cancer , 2013, Nature Reviews Urology.

[2]  F. Fuller-Pace,et al.  p68/DdX5 Supports β-Catenin & RNAP II during Androgen Receptor Mediated Transcription in Prostate Cancer , 2013, PloS one.

[3]  I. Mills,et al.  The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. , 2013, Cancer cell.

[4]  M. Taketo,et al.  β-Catenin Is Required for Prostate Development and Cooperates with Pten Loss to Drive Invasive Carcinoma , 2013, PLoS genetics.

[5]  R. Moon,et al.  WNT signalling pathways as therapeutic targets in cancer , 2012, Nature Reviews Cancer.

[6]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[7]  Judith Campisi,et al.  Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B , 2012, Nature Medicine.

[8]  J. Waxman,et al.  Wnt/β-catenin signalling in prostate cancer , 2012, Nature Reviews Urology.

[9]  Vilppu J. Tuominen,et al.  Chemical castration and anti‐androgens induce differential gene expression in prostate cancer , 2012, The Journal of pathology.

[10]  A. Jemal,et al.  International variation in prostate cancer incidence and mortality rates. , 2012, European urology.

[11]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[12]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[13]  E. Vazquez,et al.  Activation of β-Catenin Signaling in Androgen Receptor–Negative Prostate Cancer Cells , 2011, Clinical Cancer Research.

[14]  Michael Q. Zhang,et al.  Identification of Novel Androgen-Regulated Pathways and mRNA Isoforms through Genome-Wide Exon-Specific Profiling of the LNCaP Transcriptome , 2011, PloS one.

[15]  W. Weis,et al.  The beta-catenin binding protein ICAT modulates androgen receptor activity. , 2011, Molecular endocrinology.

[16]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[17]  Sarat Chandarlapaty,et al.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.

[18]  I. Pedley,et al.  Tolerability and efficacy of anti-androgen manipulation versus taxotere and anti-androgen manipulation in patients with hormone-naive, high-risk/metastatic prostate cancer: A phase II, open-labeled, randomized study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[20]  F. Zhao,et al.  Characterization of the Small RNA Transcriptomes of Androgen Dependent and Independent Prostate Cancer Cell Line by Deep Sequencing , 2010, PloS one.

[21]  M. Gleave,et al.  Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer , 2010, The Prostate.

[22]  C. Robson,et al.  Docetaxel-Resistant Prostate Cancer Cells Remain Sensitive to S-Trityl-l-Cysteine–Mediated Eg5 Inhibition , 2010, Molecular Cancer Therapeutics.

[23]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[24]  Crispin J. Miller,et al.  A comparison of massively parallel nucleotide sequencing with oligonucleotide microarrays for global transcription profiling , 2010, BMC Genomics.

[25]  Marc W. Kirschner,et al.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.

[26]  David J. Elliott,et al.  Alternative splicing and biological heterogeneity in prostate cancer , 2009, Nature Reviews Urology.

[27]  Gang Wang,et al.  Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. , 2008, Cancer research.

[28]  R. Vossen,et al.  Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platforms , 2008, Nucleic acids research.

[29]  M. Stephens,et al.  RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. , 2008, Genome research.

[30]  I. Mills,et al.  Alterations in β‐catenin expression and localization in prostate cancer , 2008, The Prostate.

[31]  A. Chinnaiyan,et al.  Recurrent gene fusions in prostate cancer , 2008, Nature Reviews Cancer.

[32]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[33]  E. Latulippe,et al.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.

[34]  Susumu Goto,et al.  The KEGG resource for deciphering the genome , 2004, Nucleic Acids Res..

[35]  D. Neal,et al.  Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development , 2003, Oncogene.

[36]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.